FACTS ABOUT HEMGENIX REVEALED

Quantity of eligible individuals: CDEC mentioned the uncertainty in the amount of individuals with moderately severe to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific gurus consulted by CADTH indicated that some clients that are categorized as getting mild or average ailment could have a extreme bleeding phenotype,

Variety of qualified sufferers: CDEC reviewed the uncertainty in the volume of clients with reasonably severe to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some sufferers who are classified as having moderate or average sickness can have a intense bleeding phenoty